JP2020533293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533293A5 JP2020533293A5 JP2020513562A JP2020513562A JP2020533293A5 JP 2020533293 A5 JP2020533293 A5 JP 2020533293A5 JP 2020513562 A JP2020513562 A JP 2020513562A JP 2020513562 A JP2020513562 A JP 2020513562A JP 2020533293 A5 JP2020533293 A5 JP 2020533293A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- cancer
- immune checkpoint
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DADASRPKWOGKCU-FVTQAUBDSA-N C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c(cc(cc5)OC)c5N5)C5=O)ccc34)cc2)C1 Chemical compound C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c(cc(cc5)OC)c5N5)C5=O)ccc34)cc2)C1 DADASRPKWOGKCU-FVTQAUBDSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023141415A JP2023155459A (ja) | 2017-09-08 | 2023-08-31 | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555718P | 2017-09-08 | 2017-09-08 | |
| US62/555,718 | 2017-09-08 | ||
| PCT/CA2018/051086 WO2019046949A1 (en) | 2017-09-08 | 2018-09-07 | POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023141415A Division JP2023155459A (ja) | 2017-09-08 | 2023-08-31 | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533293A JP2020533293A (ja) | 2020-11-19 |
| JP2020533293A5 true JP2020533293A5 (https=) | 2021-09-24 |
| JP7343483B2 JP7343483B2 (ja) | 2023-09-12 |
Family
ID=65633360
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513562A Active JP7343483B2 (ja) | 2017-09-08 | 2018-09-07 | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
| JP2023141415A Pending JP2023155459A (ja) | 2017-09-08 | 2023-08-31 | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023141415A Pending JP2023155459A (ja) | 2017-09-08 | 2023-08-31 | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12109215B2 (https=) |
| EP (1) | EP3678669A4 (https=) |
| JP (2) | JP7343483B2 (https=) |
| CN (1) | CN111225670A (https=) |
| AU (2) | AU2018328773B2 (https=) |
| CA (1) | CA3074876A1 (https=) |
| TW (1) | TWI845482B (https=) |
| WO (1) | WO2019046949A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| JP2023505301A (ja) * | 2019-12-06 | 2023-02-08 | ユニバーシティー ヘルス ネットワーク | 急性骨髄性白血病または骨髄異形成症候群に対する治療 |
| US20230165871A1 (en) * | 2020-04-06 | 2023-06-01 | University Health Network | Combination therapies for inhibition of polo-like kinase 4 |
| MX2023013225A (es) | 2021-05-11 | 2024-01-15 | Oric Pharmaceuticals Inc | Inhibidores de la cinasa 4 similar a polo. |
| WO2022266240A1 (en) * | 2021-06-16 | 2022-12-22 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5442906B2 (ja) * | 2010-04-06 | 2014-03-19 | ユニバーシティ・ヘルス・ネットワーク | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
| US8933070B2 (en) * | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| RS58413B1 (sr) * | 2013-10-18 | 2019-04-30 | Univ Health Network | So i kristalni oblici inhibitora plk-4 |
| SG11201602882VA (en) * | 2013-10-18 | 2016-05-30 | Univ Health Network | Treatment for pancreatic cancer |
| ES2686549T3 (es) * | 2014-06-16 | 2018-10-18 | Worldwide Innovative Network | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| EP3981430A1 (en) * | 2015-01-21 | 2022-04-13 | Memorial Sloan Kettering Cancer Center | Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells |
| AU2016219204B2 (en) * | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
-
2018
- 2018-09-07 AU AU2018328773A patent/AU2018328773B2/en not_active Ceased
- 2018-09-07 CN CN201880067175.0A patent/CN111225670A/zh active Pending
- 2018-09-07 TW TW107131410A patent/TWI845482B/zh not_active IP Right Cessation
- 2018-09-07 WO PCT/CA2018/051086 patent/WO2019046949A1/en not_active Ceased
- 2018-09-07 CA CA3074876A patent/CA3074876A1/en active Pending
- 2018-09-07 EP EP18854876.2A patent/EP3678669A4/en not_active Withdrawn
- 2018-09-07 US US16/644,633 patent/US12109215B2/en active Active
- 2018-09-07 JP JP2020513562A patent/JP7343483B2/ja active Active
-
2023
- 2023-08-31 JP JP2023141415A patent/JP2023155459A/ja active Pending
-
2024
- 2024-02-14 AU AU2024200937A patent/AU2024200937A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533293A5 (https=) | ||
| JP7163260B2 (ja) | 腫瘍を処置するための抗ｌａｇ－３抗体と抗ｐｄ－１抗体との組合せ | |
| JP2020522495A5 (https=) | ||
| Wang et al. | PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective | |
| Blank et al. | Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion | |
| Seliger et al. | The expression, function, and clinical relevance of B7 family members in cancer | |
| Cousin et al. | Molecular pathways: immune checkpoint antibodies and their toxicities | |
| JP2021524744A5 (https=) | ||
| HRP20211333T1 (hr) | Molekule za vezanje pd-1 i lag-3 i postupci za njihovu uporabu | |
| JP2023078394A (ja) | Ｃａｒ－ｔ細胞の調節方法 | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2018027952A5 (https=) | ||
| JP2020513828A5 (https=) | ||
| JP2020522691A5 (https=) | ||
| JP2021503927A5 (https=) | ||
| JP2017532372A5 (https=) | ||
| JP2019511212A5 (https=) | ||
| JP2018503399A5 (https=) | ||
| Feucht et al. | Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors | |
| CN113272330A (zh) | 一种双特异抗体 | |
| JP2019529418A5 (https=) | ||
| Michelakos et al. | B7-H3 targeted antibody-based immunotherapy of malignant diseases | |
| CN113164408A (zh) | 肿瘤联合免疫治疗 | |
| RU2019120849A (ru) | Противораковая композиция, содержащая рекомбинантный аденовирус, экспрессирующий разрушающий фактор для внеклеточного матрикса | |
| JP2021501801A5 (https=) |